There is a Better Way
February 9, 2010 Leave a comment
With several hundred compounds currently in development for the treatment of cancer, how will we scientists and clinical oncologists match these drugs to patients in need?
Only 8 percent of drugs entering Phase I ever make it through the highly unproductive Phase II and Phase III trial mechanisms to win FDA approval, with 50 percent failing at the Phase III final stage of development!
We can stop this self-defeating strategy and apply selective methodologies to identify the best disease targets for these compounds. According to Joanne Woodcock of the FDA, modern science has provided much more information about the origin of cancer than about its treatment. She has called for a developmental effort in the pursuit of a “critical path,” from bench to bedside.
I believe that Ex Vivo Analysis of Programmed Cell Death (EVA-PCD)® is that critical pathway and can serve to streamline drug development.